Cameron Miller
@cameronmillertbtc.bsky.social
Director of External Affairs at The Brain Tumour Charity.
Passionate about life sciences. Views my own and likes not endorsement.
Passionate about life sciences. Views my own and likes not endorsement.
Reposted by Cameron Miller
🚨Merck ditching its £1bn UK expansion must be a wake-up call for the Government.
💡While the US backs innovation, the UK is falling behind. We need a bold, cross-party life sciences strategy to attract investment and keep the UK at the forefront of global research.
💡While the US backs innovation, the UK is falling behind. We need a bold, cross-party life sciences strategy to attract investment and keep the UK at the forefront of global research.
September 11, 2025 at 1:59 PM
🚨Merck ditching its £1bn UK expansion must be a wake-up call for the Government.
💡While the US backs innovation, the UK is falling behind. We need a bold, cross-party life sciences strategy to attract investment and keep the UK at the forefront of global research.
💡While the US backs innovation, the UK is falling behind. We need a bold, cross-party life sciences strategy to attract investment and keep the UK at the forefront of global research.
Reposted by Cameron Miller
A new study from @lshtm.bsky.social highlights the disparity of survival rates between cancer types, including less survivable cancers. “The National Cancer Plan must… make meaningful strides in improving outcomes for all patients.” Read our full statement here ➡️ shorturl.at/JFlFb
A new study by the London School of Hygiene and Tropical Medicine, U. | Less Survivable Cancers Taskforce
A new study by the London School of Hygiene and Tropical Medicine, U. of London reveals further evidence of the disparity of survival rates between cancer types, including little improvements for some...
shorturl.at
August 13, 2025 at 2:05 PM
A new study from @lshtm.bsky.social highlights the disparity of survival rates between cancer types, including less survivable cancers. “The National Cancer Plan must… make meaningful strides in improving outcomes for all patients.” Read our full statement here ➡️ shorturl.at/JFlFb
@drscottarthurmp.bsky.social
Rare Cancers Bill has passed its Third Reading!
Despite their being some jeopardy earlier in the week, the whole rare disease community unified and acted to ensure that it didn’t fall.
This Bill has the chance to be transformational for rare cancer patients.
Rare Cancers Bill has passed its Third Reading!
Despite their being some jeopardy earlier in the week, the whole rare disease community unified and acted to ensure that it didn’t fall.
This Bill has the chance to be transformational for rare cancer patients.
July 11, 2025 at 3:18 PM
@drscottarthurmp.bsky.social
Rare Cancers Bill has passed its Third Reading!
Despite their being some jeopardy earlier in the week, the whole rare disease community unified and acted to ensure that it didn’t fall.
This Bill has the chance to be transformational for rare cancer patients.
Rare Cancers Bill has passed its Third Reading!
Despite their being some jeopardy earlier in the week, the whole rare disease community unified and acted to ensure that it didn’t fall.
This Bill has the chance to be transformational for rare cancer patients.
Reposted by Cameron Miller
The Taskforce supports the Rare Cancers Bill. The Bill reaches its 3rd reading in Parliament tomorrow, Friday 12 July and we need at least 40 MPs in Westminster to ensure it progresses.
👉 We are calling on all MPs to attend and support the Bill.
👉 We are calling on all MPs to attend and support the Bill.
July 10, 2025 at 1:36 PM
The Taskforce supports the Rare Cancers Bill. The Bill reaches its 3rd reading in Parliament tomorrow, Friday 12 July and we need at least 40 MPs in Westminster to ensure it progresses.
👉 We are calling on all MPs to attend and support the Bill.
👉 We are calling on all MPs to attend and support the Bill.
The Rare Cancers Bill has had months of cross party support but is in danger of not passing due to an amendment being tabled.
This is a chance to see real change for the rare cancer community, so please write to your MP and encourage them attend the Third Reading on Friday!
shorturl.at/kteH8
This is a chance to see real change for the rare cancer community, so please write to your MP and encourage them attend the Third Reading on Friday!
shorturl.at/kteH8
July 10, 2025 at 6:09 AM
The Rare Cancers Bill has had months of cross party support but is in danger of not passing due to an amendment being tabled.
This is a chance to see real change for the rare cancer community, so please write to your MP and encourage them attend the Third Reading on Friday!
shorturl.at/kteH8
This is a chance to see real change for the rare cancer community, so please write to your MP and encourage them attend the Third Reading on Friday!
shorturl.at/kteH8
A real pleasure to introduce @drscottarthurmp.bsky.social at the @cancer52org.bsky.social meeting this week and hear his motivation and hopesfor leading the Rare Cancers Bill. A chance for real change.
Proud to have been a part of this.
Proud to have been a part of this.
We’re proud to bring the rare & less common cancer community together at the #BigCancer52Conversation
So far we’ve discussed what’s next in terms of policy for rare and less common cancers with the Rare Cancers Bill and National Cancer Plan @drscottarthurmp.bsky.social @thekingsfund.bsky.social
So far we’ve discussed what’s next in terms of policy for rare and less common cancers with the Rare Cancers Bill and National Cancer Plan @drscottarthurmp.bsky.social @thekingsfund.bsky.social
June 25, 2025 at 4:45 PM
A real pleasure to introduce @drscottarthurmp.bsky.social at the @cancer52org.bsky.social meeting this week and hear his motivation and hopesfor leading the Rare Cancers Bill. A chance for real change.
Proud to have been a part of this.
Proud to have been a part of this.
Reposted by Cameron Miller
Did you know that according to data, brain tumour trials have the lowest recruitment levels of any cancer type?
Today we have launched our latest policy report exploring barriers to research participation and how these challenges can be overcome:
www.thebraintumourcharity.org/news/policy-...
Today we have launched our latest policy report exploring barriers to research participation and how these challenges can be overcome:
www.thebraintumourcharity.org/news/policy-...
Six ways to remove the barriers to research participation
Discover insights from our report on the challenges people with brain tumours face in participating in research.
www.thebraintumourcharity.org
June 12, 2025 at 12:26 PM
Did you know that according to data, brain tumour trials have the lowest recruitment levels of any cancer type?
Today we have launched our latest policy report exploring barriers to research participation and how these challenges can be overcome:
www.thebraintumourcharity.org/news/policy-...
Today we have launched our latest policy report exploring barriers to research participation and how these challenges can be overcome:
www.thebraintumourcharity.org/news/policy-...
Reposted by Cameron Miller
An ultra-rapid method of genetically diagnosing brain tumours has been developed, cutting the classification time from 6-8 weeks, to as little as two hours. This could remove the uncertainty that those face waiting weeks for their diagnosis and prognosis. Read more: bit.ly/3YU9Qbb
May 21, 2025 at 8:23 AM
An ultra-rapid method of genetically diagnosing brain tumours has been developed, cutting the classification time from 6-8 weeks, to as little as two hours. This could remove the uncertainty that those face waiting weeks for their diagnosis and prognosis. Read more: bit.ly/3YU9Qbb
Reposted by Cameron Miller
Our new report reveals a third of respondents didn’t know they could directly request brain scans for suspected brain tumours. Even among those who did, many weren’t clear on how to use this guidance. 🧵
May 1, 2025 at 2:36 PM
Our new report reveals a third of respondents didn’t know they could directly request brain scans for suspected brain tumours. Even among those who did, many weren’t clear on how to use this guidance. 🧵